Medical University of Innsbruck

The Institute of Pathology, Neuropathology and Molecular pathology, Medical University of Innsbruck is specialized in diagnostics, research and education of many diseases and makes the claim to become the excellence center in Western Austria. The research group of Prof. Dr. Johannes Haybaeck focuses on the role of Eukaryotic translation factors in various cancer types.

Role of institution in the project

The MUI on behalf of the Institute of Pathology, Neuropathology and Molecular Pathology offers expertise in Radiology, Oncology, Data interoperability and Research infrastructure.

Prof. Johannes Haybaeck

Johannes Haybaeck is a Full Professor and Chairman of the Institute of Pathology, Neuropathology and Molecular Pathology at the Medical University of Innsbruck (MUI). He is board certified Pathologist, Molecular Pathologist, Neuropathologist and trained in Molecular Biology. He received his first degree in medicine from the University of Innsbruck. He has been trained at several Universities like the University of Zurich, Innsbruck and Salzburg. He worked for several years at the Institute of Neuropathology, University Hospital Zurich. He received his PhD degree from the Mathematical and Natural Science Faculty of the University of Zurich, Switzerland. Since 2001 he has been working as pathologist. Since 2010 he has been leading his own research group. In 2011 he became Vice Chair and since 2014 he has been the Chair of the Department of Neuropathology of the Institute of Pathology, MUG. He was elected as Founding Coordinator for Cancer Research at the Comprehensive Cancer Center Graz. Since 2018 he has been Chair of the Institute of Pathology, Neuropathology and Molecular Pathology at the MUI. Since 2020 he has been coordinator of the newly established Central Biobank Innsbruck and thereby also strongly involved in the actions of the European research infrastructure for biobanking (BBMRI-ERIC).

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.